Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | The AVANOVA study: niraparib and bevacizumab for ovarian cancer

In this video, Mansoor Raza Mirza, MD, of the Copenhagen University Hospital, Copenhagen, Denmark, discusses the AVANOVA study (NCT02354131) of niraparib and bevacizumab for treating ovarian cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.